Celltrion’s Truxima, a leading **blood cancer treatment**, has achieved a significant milestone by becoming the **most prescribed rituximab drug** in the **United States life sciences market**. This achievement marks Truxima as the first **Korean biosimilar** to dominate its segment within the **world’s largest pharmaceutical market**, as announced by the company on Tuesday.
Insights from **IQVIA**, a renowned life sciences market analytics firm, reveal that **Truxima**, developed by Celltrion as a robust **rituximab biosimilar**, secured a substantial **35.8 percent prescription share in the U.S.** as of February this year. This remarkable market penetration was achieved approximately six years and three months following its initial **U.S. launch** in November 2019.
Beyond prescription volume, **Truxima’s record-setting performance** extends to its impressive financial results. **Celltrion** reported that **Truxima sales** in **North America** surpassed 300 billion won ($198 million) last year, marking an approximate 40 percent increase from 2024 figures. This strong growth firmly establishes **Truxima** as a crucial and **key product** for the **Korean biosimilar maker**.
**Celltrion** highlighted that **Truxima’s success** underscores expanding **business opportunities** for the company. This growth trajectory is particularly significant given the **U.S. government’s decision to exclude biosimilars from tariffs**, a beneficial policy for Celltrion, which primarily derives its revenue from **biosimilar sales**.
A **Celltrion official** commented, “Truxima’s ascent to the **No. 1 prescription spot in the U.S.**, the **world’s largest pharmaceutical market**, by surpassing even original reference drugs, is poised to significantly boost its **product awareness and preference** among healthcare professionals and patients.”
“With both our **existing biosimilar portfolio** and **newly launched products** consistently delivering **strong performances globally**, including within the **U.S. market**, we are confident in achieving our **annual earnings target** for the current year,” the official added.
hwkan
